

PyCoStat: Pycnogenol®, coenzyme Q10 and patients treated with statins

Submission date 16/02/2023	Recruitment status Recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 10/03/2023	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 11/09/2024	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Dyslipidemia, an imbalance of fats in the blood, is one of the most common modifiable risk factors for cardiovascular disease, in which statins are recommended as first-line pharmacological therapy. Treatment with statins reduces the risk of heart attack and stroke in most patients with elevated low-density lipoprotein (LDL) cholesterol levels and in most high-risk patients with atherosclerotic cardiovascular disease. Statins are well tolerated in most adult patients with a low incidence of minor adverse effects. However, they are associated with various side effects on skeletal muscle - from mild to severe. The mechanism of statin-associated muscle symptoms (SAMS) is currently unclear, but changes in blood coenzyme Q10 (CoQ10) levels may be involved in the pathological process. CoQ10 is an intracellular antioxidant that protects membrane phospholipids, mitochondrial membrane proteins, and LDL particles from oxidative damage caused by free radicals. Statins, by their inhibitory effect on the cholesterol synthesis pathway, can reduce not only cholesterol synthesis but also the synthesis of other molecules that arise from mevalonate, including CoQ10. Pycnogenol® is a standardized pine bark extract of *Pinus pinaster* Aiton and shows different effects in humans after oral administration, e.g. antioxidant, anti-inflammatory, antiallergic, hypolipidemic etc., which have been demonstrated in many clinical studies. The aim of this study is to investigate how 3 months of daily administration of Pycnogenol® (150 mg/day) by patients treated with statins affect CoQ10 levels in the blood, the serum lipid balance, LDL and high-density lipoprotein (HDL) subfraction levels, lipoprotein (a) (Lp(A)) and apolipoprotein-A1 (Apo-A1) levels, level of oxidative stress, the antioxidant status of the patients and adverse effects of statins related to muscles – weakness, pain, tiredness.

Who can participate?

Adults aged 19 to 60 years who are being treated for the first time with statins

What does the study involve?

In this study, the effects of Pycnogenol® (PYC- group) on the status of patients with dyslipidemia, who are treated with statins for the first time will be compared with placebo (PL-group). Patients who meet the inclusion criteria, after initial medical investigation (complete medical history and examination, questionnaire about quality of life) will be allocated to one of the two arms of the project (PYC or PL-group) in a ratio of 1:1, according to a computer-

generated random sequence (visit 1). The randomisation will be performed by a statistician, who will have no contact with the participants. Patients will be administered 150 mg Pycnogenol® or Placebo for 3 months. After the intervention period, patients will be examined by the doctor and patients will fill out a questionnaire about quality of life (visit 2). At both visits, blood samples will be taken. The research team and participants will be unaware of the group assignments.

What are the possible benefits and risks of participating?

Participants who receive Pycnogenol® may benefit from the improvement of statin-associated muscle symptoms, quality of life and antioxidant status. There are no known risks to participants taking part in this study.

Where is the study run from?

1. Institute of Medical Chemistry, Biochemistry and Clinical Biochemistry, Comenius University, Bratislava (Slovakia)
2. 1st Department of Internal Medicine, Faculty of Medicine, Comenius University and University Hospital, Bratislava (Slovakia)

When is the study starting and how long is it expected to run for?

May 2022 to December 2025

Who is funding the study?

Horphag Research Ltd (Switzerland)

Who is the main contact?

RN Dr Országhová Zuzana, PhD, zuzana.orszaghova@fmed.uniba.sk (Slovakia)

Contact information

Type(s)

Principal Investigator

Contact name

Dr Zuzana Orszaghova

ORCID ID

<https://orcid.org/0000-0003-2978-9431>

Contact details

Sasinkova 2

Bratislava

Slovakia

81108

+421 2 90119412

zuzana.orszaghova@fmed.uniba.sk

Type(s)

Scientific

Contact name

Dr Institute of Medical Chemistry Biochemistry and Clinical Biochemistry

Contact details

Sasinkova 2
Bratislava
Slovakia
81108
+421290119411
jana.muchova@fmed.uniba.sk

Type(s)

Public

Contact name

Dr Institute of Medical Chemistry Biochemistry and Clinical Biochemistry

Contact details

Sasinkova 2
Bratislava
Slovakia
81108
+421290119411
jana.muchova@fmed.uniba.sk

Additional identifiers**EudraCT/CTIS number**

Nil known

IRAS number**ClinicalTrials.gov number**

Nil known

Secondary identifying numbers

Nil known

Study information**Scientific Title**

Effect of maritime pine bark extract (Pycnogenol®) on CoQ10 levels and wellbeing in patients treated with statins

Acronym

PyCoStat

Study objectives

The aim of the study is to investigate how the oral administration of Pycnogenol® (150 mg/day) by patients treated with statins affects coenzyme Q10 (CoQ10) levels in the blood, the serum lipid profile, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subfractions,

lipoprotein (a) (Lp(A)) and apolipoprotein-A1 (Apo-A1) levels, level of oxidative stress and antioxidant status of the patients and adverse effects of statins related to muscles – weakness, pain, tiredness.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 24/10/2022, Ethics Committee of Faculty of Medicine, Comenius University and University Hospital in Bratislava (Old Town Hospital, Mickiewiczova 13, 81369 Bratislava, Slovakia; +421 2 57 290 495; jan.pecenak@sm.unb.sk), ref: 69/2022

Study design

Interventional double-blinded randomized placebo-controlled study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Community, Medical and other records

Study type(s)

Quality of life

Participant information sheet

Not available in web format

Health condition(s) or problem(s) studied

Patients treated with statins for the first time

Interventions

The randomization will be performed by a statistician, who will have no contact with the participants. The research team and participants will be unaware of the group assignments and the envelope with assignments will be opened only after analyses are finished and databases are completed and locked.

Participants randomised into active or placebo groups will be required to take three capsules a day for 3 months:

1. Active intervention: 50 mg of a standardised extract from pine bark – Pycnogenol® per capsule
2. Placebo intervention: maltodextrin without the active substances, identically packaged as active.

Both interventions will be prepared by Horphag Research Ltd. (Geneva, Switzerland).

As part of the project, patients make two visits to the doctor, they will be examined, blood will be taken and a quality of life questionnaire will be undertaken.

Intervention Type

Supplement

Primary outcome measure

1. Quality of life and side symptoms of statin treatment measured using the 12-Item Short Form Survey (SF-12) questionnaire at baseline and after 3 months of intervention
2. CoQ10 levels in the blood HPLC at baseline and after 3 months of intervention

Secondary outcome measures

1. Basic and specific biochemical parameters - fasting glucose, creatinine, urea, lipid profile (total cholesterol, HDL-cholesterol, LDL-cholesterol, TAG), CRP, apolipoprotein A1, lipoprotein(a) measured at certified Laboratory of Clinical Biochemistry using Roche tests at baseline and after 3 months of intervention
2. HDL and LDL subfractions measured using an electrophoretic Lipoprint system at baseline and after 3 months of intervention
3. Total antioxidant capacity of plasma measured using the TEAC method and the levels of selected antioxidants (alpha-tocopherol, gamma-tocopherol, beta-carotene, glutathione) in thrombocytes, blood and plasma measured using spectrophotometric or fluorometric methods at baseline and after 3 months of intervention
4. The parameters of oxidative damage to lipids (oxLDL, lipoperoxide, TBARS) in plasma measured using spectrophotometric methods at baseline and after 3 months of intervention
5. Activities of PON 1 (arylesterase and lactonase) using spectrophotometric methods at baseline and after 3 months of intervention
6. Activity of creatine kinase (isoenzyme MM) measured at certified Laboratory of Clinical Biochemistry at baseline and after 3 months of intervention

Overall study start date

01/05/2022

Completion date

31/12/2025

Eligibility

Key inclusion criteria

Patients with different diagnoses (e.g. CVD, hypertension) who will be treated with any type of statin for the first time and in a dose that will be determined individually based on the established overall CV risk with the aim of achieving target lipid values

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

60 participants, 30 in active group and 30 in placebo group.

Key exclusion criteria

1. Aged < 19 and > 60 years old
2. Acute myocardial infarction (IM) or less than 3 months after IM
3. Active oncological disease
4. Hypothyroidism
5. Diabetes Mellitus
6. Chronic inflammatory disease (e.g. rheumatoid arthritis)
7. Unable/unwilling to sign an informed consent
8. Unable/unwilling to provide samples of biological material as needed

Date of first enrolment

06/03/2023

Date of final enrolment

30/09/2025

Locations

Countries of recruitment

Slovakia

Study participating centre

Comenius University and University Hospital

1st Department of Internal Medicine

Faculty of Medicine

Mickiewiczova 13

Bratislava

Slovakia

81369

Study participating centre

Comenius University

Institute of Medical Chemistry, Biochemistry and Clinical Biochemistry

Faculty of Medicine

Sasinkova 2

Bratislava

Slovakia

81108

Sponsor information

Organisation

Horphag Research (Switzerland)

Sponsor details

71, Avenue Louis Casà
Geneva
Switzerland
CH-1216 Cointrin
+41 (0)22 710 26 26
carolina.burki@horphag.com

Sponsor type

Industry

Website

<http://www.pycnogenol.com>

ROR

<https://ror.org/003n34405>

Funder(s)

Funder type

Industry

Funder Name

Horphag Research (Switzerland)

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal

Intention to publish date

30/06/2026

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from zuzana.orszaghova@fmed.uniba.sk

IPD sharing plan summary

Available on request